Deploys private capital into growth-stage technology and healthcare companies, combining active board work with financial and operational playbooks to drive scale and exit readiness. Adam Amante brings experience across venture and corporate development roles, leading deal execution, diligence and post-investment value creation for minority and control investments. Market relevance centers on revenue-driven growth strategies, partnerships that accelerate distribution, and pragmatic governance improvements to improve liquidity timelines.
Deploys private capital into growth-stage technology and healthcare companies, combining active board work with financial and operational playbooks to drive scale and exit readiness. Adam Amante brings experience across venture and corporate development roles, leading deal execution, diligence and post-investment value creation for minority and control investments. Market relevance centers on revenue-driven growth strategies, partnerships that accelerate distribution, and pragmatic governance improvements to improve liquidity timelines.
Focuses on growth-stage technology and healthcare investments, combining minority and control stakes with active board involvement and hands-on operational playbooks to accelerate scale and exit readiness. Underwrites opportunities through revenue and unit-economics-driven diligence, prioritizing capital efficiency, commercial partnerships that expand distribution, and governance fixes that shorten liquidity timelines. Deploys milestone-based capital, targets three- to seven-year horizons, and leans on repeatable go-to-market and partnership plays to de-risk execution.
Focuses on growth-stage technology and healthcare investments, combining minority and control stakes with active board involvement and hands-on operational playbooks to accelerate scale and exit readiness. Underwrites opportunities through revenue and unit-economics-driven diligence, prioritizing capital efficiency, commercial partnerships that expand distribution, and governance fixes that shorten liquidity timelines. Deploys milestone-based capital, targets three- to seven-year horizons, and leans on repeatable go-to-market and partnership plays to de-risk execution.
| Trades 340 | Longs Won 210/340 61% | Profit Factor 10.25 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $238,656.49 |
| Average Win $89,373.81 | Best Trade (Jul 15) $3.59M | Sharpe Ratio -9.72 |
| Average Loss -$14,079.01 | Worst Trade (Jul 14) -$270,689.97 | Z-Score 3.9 (100%) |
| Commissions $0 | Avg. Trade Length 9m 3w 5d | Expectancy $49,818.32 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 7,407 | 6,667 | 5,926 | 5,185 | 4,444 | 3,704 | 2,963 | 2,222 | 1,481 | 741 |